全文获取类型
收费全文 | 310397篇 |
免费 | 47930篇 |
国内免费 | 13350篇 |
专业分类
耳鼻咽喉 | 6818篇 |
儿科学 | 7545篇 |
妇产科学 | 3722篇 |
基础医学 | 17950篇 |
口腔科学 | 4337篇 |
临床医学 | 46401篇 |
内科学 | 66606篇 |
皮肤病学 | 9254篇 |
神经病学 | 21036篇 |
特种医学 | 12456篇 |
外国民族医学 | 70篇 |
外科学 | 57145篇 |
综合类 | 35983篇 |
现状与发展 | 114篇 |
一般理论 | 10篇 |
预防医学 | 20582篇 |
眼科学 | 6959篇 |
药学 | 18341篇 |
190篇 | |
中国医学 | 12617篇 |
肿瘤学 | 23541篇 |
出版年
2024年 | 1044篇 |
2023年 | 6751篇 |
2022年 | 6514篇 |
2021年 | 10694篇 |
2020年 | 12065篇 |
2019年 | 6729篇 |
2018年 | 12268篇 |
2017年 | 12355篇 |
2016年 | 13080篇 |
2015年 | 16034篇 |
2014年 | 24812篇 |
2013年 | 25301篇 |
2012年 | 19589篇 |
2011年 | 20665篇 |
2010年 | 21799篇 |
2009年 | 23799篇 |
2008年 | 16515篇 |
2007年 | 14316篇 |
2006年 | 16133篇 |
2005年 | 11923篇 |
2004年 | 8801篇 |
2003年 | 7433篇 |
2002年 | 6524篇 |
2001年 | 7218篇 |
2000年 | 5653篇 |
1999年 | 5241篇 |
1998年 | 4801篇 |
1997年 | 4561篇 |
1996年 | 4234篇 |
1995年 | 3997篇 |
1994年 | 2548篇 |
1993年 | 1942篇 |
1992年 | 1774篇 |
1991年 | 1726篇 |
1990年 | 1349篇 |
1989年 | 1401篇 |
1988年 | 1209篇 |
1987年 | 1035篇 |
1986年 | 1028篇 |
1985年 | 824篇 |
1984年 | 600篇 |
1983年 | 561篇 |
1982年 | 544篇 |
1981年 | 436篇 |
1980年 | 378篇 |
1979年 | 348篇 |
1978年 | 345篇 |
1977年 | 415篇 |
1975年 | 289篇 |
1972年 | 311篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
15.
16.
目的 探讨低危单胎的足月妊娠自然临产后,潜伏期脑胎盘率(CPR)对预测新生儿不良结局的价值。方法 选取2018年1月至2021年3月我院住院临产分娩的673例孕妇为研究对象,测量胎儿大脑中动脉、脐动脉血流参数,获得分娩结局及新生儿结局。参考既往研究得出的不同孕周CPR正常参考值百分位作为分组指标(CPR≤10%参考值定为低CPR)。比较低CPR组(72例)与正常CPR组(601例)两组妊娠结局、新生儿不良结局。结果 低CPR组与正常CPR组在孕妇年龄、孕龄、产次、孕期体质量增长、总产程、新生儿体质量的构成上差异均无统计学意义(P>0.05)。低CPR组因胎儿窘迫行剖宫产或助产发生率、新生儿任一不良结局发生率、新生儿不良结局率均高于正常CPR组,差异均有统计学意义(P<0.05)。低CPR预测新生儿不良结局的准确率为89.5%(602/673),敏感度为51.7%(15/29),特异度为91.1%(587/644)。结论 本研究数据显示,对于无并发症及合并症、低风险的单胎足月妊娠,潜伏期低CPR与新生儿不良结局相关。 相似文献
17.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
18.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
19.
卫逸涛肖惠敏谢银环孙丽军 《中华健康管理学杂志》2022,(8):547-552
目的了解老年人生命晚期获知疾病相关信息意向及影响因素。方法2016年10月至2017年6月,采用生命晚期疾病信息意向问卷,利用方便抽样法对福州市中心城区7所养老机构及15个社区的414例年龄≥60岁的老年人进行横断面调查,采用单因素分析、多元线性回归与有序多分类logistic回归分析老年人对疾病相关信息的需求水平、获知程度意向及其影响因素。结果414例老年人疾病相关信息需求得分为(17.1±4.9)分;48.8%(202/414)希望详尽知晓,30.7%(127/414)希望选择性了解,20.5%(85/414)不想知道任何信息;多元线性回归分析显示,年龄、文化程度、是否接受/见过其他生命维持治疗(LSTs)是影响老年人疾病相关信息需求水平的主要因素(标准化回归系数分别为-0.141、0.116、0.115,均P<0.05);有序多分类logistic分析显示,年龄(以60~69岁为参照,70~79岁:OR=0.544,95%CI:0.310~0.957;80~89岁:OR=0.526,95%CI:0.289~0.956)、文化程度(以小学及以下为参照,大专及以上:OR=2.166,95%CI:1.093~4.290)、主要生活费来源(以其他补贴为参照,家人支持:OR=7.303,95%CI:1.157~46.108;退休金:OR=9.288,95%CI:1.502~57.415;公积金/储蓄:OR=15.676,95%CI:2.122~115.793)、是否接受/见过其他LSTs(以是为参照,OR=1.985,95%CI:1.150~3.425)是影响老年人疾病相关信息获知程度意向的主要因素。结论老年人生命晚期获知疾病相关信息的意向程度较高,年龄、文化程度、主要生活费来源、是否接受/见过其他生命维持治疗等是其主要影响因素。 相似文献
20.